Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome

Bouwhuis, Saskia A.; el-Azhary, Rokea A.; Gibson, Lawrence E.; McEvoy, Marian T.; Pittelkow, Mark R.

doi:10.1067/mjd.2002.124069

Cited by 11 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[148][149][150] The overall RR for ECP monotherapy has ranged from 36% in an intention-to-treat analysis 149 to 10%, 17%, 50%, 80%, and 83% in those patients with MF/SS who have been on ECP for at least 3 months. 84,90,149,151 Edelson et al 152 reported a response ( $ 25%) in 83% (24 of 29) of patients with E-MF (blood involvement not given). Those studies in which SS has been clearly defined and an OR defined as at least 50% clearing are shown in Table I.…”

Section: Extracorporeal Photopheresismentioning

confidence: 96%

“…Those studies in which SS has been clearly defined and an OR defined as at least 50% clearing are shown in Table I. 84,90,151,[153][154][155][156][157][158] However, there are notable publications where response in patients with SS to ECP (given as 2 consecutive days monthly) is defined only as at least 25% clearing. Not surprisingly, the RR is higher in these cases: de Misa et al 158 reported on 60% response in the skin in 10 patients with SS (defined as T 4 1 [5% peripheral blood SC 1 clonal involvement) and Evans et al 159 noted a response in skin in 57% of patients with SS (defined stringently as T 4 , $ 10% peripheral blood SC, and clonality TCR gene rearrangement).…”

Section: Extracorporeal Photopheresismentioning

confidence: 99%

See 1 more Smart Citation

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Olsen

Rook

Zic

et al. 2011

Journal of the American Academy of Dermatology

156

135

View full text Add to dashboard Cite

Section: Extracorporeal Photopheresismentioning

confidence: 96%

Section: Extracorporeal Photopheresismentioning

confidence: 99%

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Olsen

Rook

Zic

et al. 2011

Journal of the American Academy of Dermatology

156

135

View full text Add to dashboard Cite

“…Extracorporeal photopheresis is a recommended treatment for MF/SS, particularly for patients with blood involvement [45]. In a retrospective single center study of patients ( N = 55) with stage III–IVB SS, 37/44 (84%) responders had >50% improvement in pruritus [76]. Low-dose methotrexate is also included in NCCN recommendations, and has a history of being used to treat patients with CTCL [45, 77].…”

Section: Clinical Studies Of Systemic Anti-lymphoma Agents Includingmentioning

confidence: 99%

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

Field

Gao

Motwani

et al. 2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous and relatively rare group of non-Hodgkin lymphomas arising from neoplastic skin-homing memory T cells. There is no known cure for CTCL, and current treatments focus on achieving and maintaining remission, controlling symptoms, limiting toxicities and maintaining or improving quality of life. Patients with CTCL often suffer from pruritus (itching), which can be debilitating and can have a significant impact on physical well-being and quality of life. Although progress has been made towards understanding the mechanisms of pruritus, the pathophysiology of CTCL-related pruritus remains unclear. Currently, there is neither a step-wise treatment algorithm for CTCL nor a standardized approach to treating pruritus in patients with CTCL. Treatments which specifically target pruritus have been reported with varying effectiveness. However, systemic treatments that target CTCL have the potential to alleviate pruritus by treating the underlying disease. Several systemic CTCL treatments have reported anti-pruritic properties, some in both objective responders and nonresponders, but the lack of a standardized method to measure and report pruritus makes it difficult to compare the effectiveness of systemic treatments. In this review, we provide an overview of approved and investigational systemic CTCL treatments that report anti-pruritic properties. For each study, the methods used to measure and report pruritus, as well as the study design are examined so that the clinical benefits of each systemic treatment can be more readily evaluated. Funding: Financial support for medical editorial assistance and article processing charge were provided by Celgene Corporation.

show abstract

“…Sin embargo, son pocos los estudios que han evaluado la efectividad de la FEC como monoterapia. La respuesta, definida como mejoría > 50% del compromiso cutáneo, es aproximadamente de 25% [18][19][20][21][22] . El promedio de respuesta completa en este grupo fue cercana a 10%.…”

Section: Fotoféresis Extracorpórea (Fec)unclassified

Fotoféresis en el tratamiento de Síndrome de Sézary: Caso clínico

et al. 2015

View full text Add to dashboard Cite

Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome

Cited by 11 publications

References 46 publications

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

Fotoféresis en el tratamiento de Síndrome de Sézary: Caso clínico

Contact Info

Product

Resources

About